VERTEX PHARMACEUTICALS INC / MA Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, conversion of convertible securities for the quarter ending 2013-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, conversion of convertible securities for the quarter ending 2013-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, conversion of convertible securities for the quarter ending 2010-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, conversion of convertible securities for fiscal 2013 was $402.26M.
- VERTEX PHARMACEUTICALS INC / MA stock issued during period, value, conversion of convertible securities for fiscal 2010 was $31.57M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | $402.26M 10-K · filed 2016-02-16 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $31.57M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |